# Diabetes Research Hub — Monitor Report

**Run date:** 2026-08-02 (automated, unattended)
**Scope:** Review of latest script outputs in `Analysis/Results/`, snapshot comparison, and web breaking-news check. No existing files were modified (review-only run).

Confidence tags follow the Research Doctrine: **[Certain]** = read directly from files / independently verifiable, **[Likely]** = strong inference, **[Guessing]** = gap-filling.

---

## Headline (read this first)

**Nothing changed in the pipeline since yesterday — and that is the problem.**

1. **The baseline feeds are now frozen for a FIFTH consecutive cycle.** `clinical_trials_latest.json` and `pubmed_recent_latest.json` are both still stuck at **2026-07-17 — now 16 days stale**, two full days past the doctrine's 14-day threshold. No new trial or PubMed snapshot has appeared since 07-17 (latest snapshot files remain `*_2026-07-17.json`). Yesterday's report explicitly warned *"this should not reach a fifth cycle."* It has. **This is no longer a monitoring finding — it is an unresolved operational failure that needs a human at the scheduler and the two script logs today.** [Certain]

2. **No genuinely new external signal this cycle.** The web check surfaced only items already captured last cycle: Lilly's retatrutide TRIUMPH-2/-3 Phase 3 topline (announced 2026-07-23, now 10 days old — outside the strict 7-day window) and the Tzield/teplizumab pediatric Stage 3 T1D approval (July 2026). Orforglipron ACHIEVE-2 superiority-vs-dapagliflozin data appeared in ADA 2026 coverage but is not new this week. Nothing new requires action beyond what is already listed below. [Certain — web-checked]

3. **One small positive:** the `agent_state.json` backup job recovered — `agent_state.json.bak_2026-08-01` now exists (it had skipped 07-31). The gap runner and hub-state jobs also still fire. So the scheduler is *partially* alive; only the two baseline-data jobs are dead. That narrows the diagnosis. [Certain]

---

## File System Status

| File | Last modified | Age | Status |
|------|---------------|-----|--------|
| `clinical_trials_latest.json` | 2026-07-17 | 16 d | **STALE — 2 d past threshold** |
| `pubmed_recent_latest.json` | 2026-07-17 | 16 d | **STALE — 2 d past threshold** |
| `hub_monitor_report.md` | 2026-07-17 | 16 d | **Stale (hub_monitor.py not re-run since 07-17)** |
| `literature_gap_data.json` | 2026-07-18 | 15 d | **Stale** |
| `literature_gap_report.md` | 2026-08-01 | 1 d | Fresh wrapper, **07-17 source data** |
| `agent_state.json` | 2026-08-01 | 1 d | Fresh |
| `agent_state.json.bak_*` | 2026-08-01 | 1 d | **Backup recovered** (07-31 skip resolved) |

- Latest trial snapshot: `clinical_trials_snapshot_2026-07-17.json` — **no new snapshot in 16 days.** [Certain]
- Latest PubMed snapshot: `pubmed_recent_snapshot_2026-07-17.json` — same 16-day gap. [Certain]
- Note: `hub_monitor_report.md` itself is now stale (last scan 07-17), so its "827 result files older than 14 days" flag and its automated snapshot diffs are 16 days out of date and cannot be relied on this cycle. [Certain]

**Interpretation [Likely]:** The failure is isolated to the two data-collection jobs. `hub_monitor.py` last ran 07-17; the gap runner and agent-state jobs still run daily. Root cause is almost certainly one of: expired/blocked ClinicalTrials.gov + PubMed API access, a disabled scheduler entry for the two baseline scripts, or a changed hub-root path (the 07-17 hub monitor referenced `/sessions/intelligent-bold-bardeen/...`, a different session root than the current run). Because *both* baseline jobs died on the same date while others survived, a shared trigger/credential for those two is the most likely single point of failure.

---

## Clinical Trial Changes

Source: `clinical_trials_latest.json` (generated 2026-07-17T02:05:53, ClinicalTrials.gov API v2). **858 trials** — T1D Cure & Cell Therapy 152, T1D Immunotherapy & Prevention 76, T2D Novel Therapies (Ph 2–3) 147, Devices 236, Recently Completed w/ Results 321 (categories overlap; re-read from `metadata.category_counts` this run). [Certain]

**No snapshot diff exists since 07-17** — no new/changed/removed trials can be computed this cycle. Every entry below is the frozen 07-17 state. [Certain]

### Phase 3 RECRUITING — key-organization trials to watch (frozen 07-17) [Certain, re-verified from source JSON]

| NCT | Sponsor | Therapy / focus |
|-----|---------|-----------------|
| NCT06832410 | Vertex | Islet cell therapy (biologic) — Phase 3 |
| NCT04786262 | Vertex | VX-880 / zimislecel — Phase 3 |
| NCT07076199 | Novo Nordisk | Insulin icodec (weekly) |
| NCT07564414 | Novo Nordisk | CagriSema vs semaglutide |
| NCT07222332 | Eli Lilly | Baricitinib (preserve beta-cell function) |
| NCT07222137 | Eli Lilly | Baricitinib (delay Stage 3 T1D) |
| NCT07088068 | Sanofi | Teplizumab vs placebo |
| NCT06739122 | Eli Lilly | Dulaglutide |
| NCT07662044 / 07662109 / 07662213 / 07662135 | AstraZeneca | Elecoglipron (± dapagliflozin / semaglutide) |

Watchlist entries unchanged from last cycle: both Vertex zimislecel trials, both Lilly baricitinib trials, the Sanofi teplizumab trial, the Novo CagriSema trial, and the four AstraZeneca elecoglipron Phase 3 trials. All 16 days unrefreshed.

### Recently posted results (frozen list) [Certain]

The five watchlist-relevant results from the 07-17 snapshot are unchanged (orforglipron NCT05086445 posted 07-16; tirzepatide vs dulaglutide NCT04255433 posted 07-08; icodec NCT06340854 posted 07-02; Bayer finerenone+empagliflozin; JHU social-risk CDS). Treat as already reviewed. **No new results are detectable while the feed is frozen.** [Certain]

---

## PubMed Highlights

Source: `pubmed_recent_latest.json` (generated 2026-07-17T02:06:39, 30-day lookback, **158 unique papers**, 16 domains). Frozen — identical corpus to the last four cycles. [Certain — re-read this run]

**Cross-domain papers (highest value).** Unchanged from the frozen corpus; top hits [Certain]:

- **[42459945]** *A framework for assessing algorithmic discrimination risks in training data: pediatric type 1 diabetes* — **AI/ML + Closed Loop AP + Health Equity** (3 domains). Aligns with Tier-1 epidemiology/equity work.
- **[42419792]** *Comparative effects of drugs for adults with overweight or obesity (systematic review)* — mentions **orforglipron + retatrutide + CagriSema** together.
- [42437645] Variant-specific pharmacophoric shifts in GLP-1 receptor (GLP-1 pharmacogenomics).
- [42411999] T1D driven by residual recipient T cells after HSCT (stem-cell cure + immunotherapy).
- [42436543] Dynamics of healthcare inequalities in T2D (remission + health equity).

**Key-therapy mention counts (`therapy_hits`, 30-day, frozen 07-17), re-read this run** [Certain]:

| Therapy | total_count | paper_count |
|---------|-------------|-------------|
| dapagliflozin | 52 | 5 |
| orforglipron | 10 | 5 |
| CagriSema | 6 | 5 |
| retatrutide | 4 | 4 |
| teplizumab | 4 | 4 |
| icodec | 3 | 3 |
| baricitinib | 2 | 2 |
| **zimislecel** | **0** | **0** |

The **zimislecel gap persists (0 hits despite two active Phase 3 trials)** — almost certainly a terminology miss; the alert is likely still keyed to "VX-880" and not the "zimislecel" INN. Worth patching in `baseline_pubmed_alerts.py`. No volume-trend read is meaningful while the feed is frozen. [Certain]

---

## Gap Analysis Summary

Source: `literature_gap_report.md` (regenerated 2026-08-01, **data range through 2026/07/17**). Validation level **BRONZE** — single analytical source; requires expert confirmation. The wrapper re-ran but reprocesses the same frozen 07-17 corpus, so results are identical to last cycle. [Certain]

Top under-researched intersections (Gap Score 100 = zero joint publications):

1. **Treg / CAR-T × Neuropathy** — 100.0, 0 joint pubs
2. **Beta Cell Regen × Health Equity** — 100.0, 0
3. **Treg / CAR-T × Health Equity** — 100.0, 0
4. **Glucokinase × Health Equity** — 100.0, 0
5. **Gene Therapy × LADA** — 100.0, 0

(Also flagged: Drug Repurposing × Health Equity 100.0; Insulin Resistance × Islet Transplant 91.9.)

**Tier-1 alignment [Likely]:** The Doctrine's Tier-1 areas (re-read this run) are Multi-Omics Integration, Literature Synthesis/Gap Analysis, Clinical Trial Intelligence, Drug Repurposing, AI/ML Prediction, and Epidemiological Data Analysis. Among the top gaps, the one mapping cleanly onto *two* Tier-1 capabilities is **Drug Repurposing × Health Equity (100.0)** — Drug Repurposing (Tier-1 #4) × Epidemiological/equity analysis (Tier-1 #6), both areas with existing data access and tooling. Beta Cell Regen, Treg/CAR-T, Glucokinase, and Gene Therapy are not themselves Tier-1 domains. Per doctrine, verify each gap is real (combined-term PubMed search + Cochrane/PROSPERO check) before acting — **BRONZE findings are not actionable as-is.** Nothing here has changed since last cycle. [Certain]

---

## Breaking News (web check, last 7 days)

**No genuinely new significant event inside the 7-day window this cycle.** [Certain — web-checked 2026-08-02]

Standing context (already flagged in prior cycles, not new this week):

- **Retatrutide — positive Phase 3 topline, TRIUMPH-2 & TRIUMPH-3 (announced 2026-07-23, now 10 days old).** Lilly's GIP/GLP-1/glucagon triple agonist; substantial weight loss and glycemic improvement at 80 weeks; BLA to FDA planned Q1 2027. On our therapy watchlist. Confirm it is in the tracker if not already. [Certain]
- **Tzield (teplizumab, Sanofi) accelerated approval — Stage 3 T1D, children 8–17 (July 2026),** on the Phase III PROTECT trial (n=328). First disease-modifying therapy for newly-diagnosed pediatric Stage 3 T1D. Confirm tracker records this; if so, teplizumab graduates from watchlist to approved for this indication. [Certain]
- **Orforglipron ACHIEVE-2 (NCT06192108):** superiority over dapagliflozin in adults inadequately controlled on metformin (ADA 2026 coverage). Not new this week. [Likely]
- **Vertex zimislecel (VX-880):** still investigational; global regulatory submissions expected during 2026, realistic approval 2027–2028. No confirmed new July/August-2026 filing found. [Likely]

---

## Recommended Actions

Ranked by urgency.

1. **[ESCALATE — 5th consecutive cycle] Re-run the two stalled baseline scripts and read their logs today:**
   - `python baseline_clinical_trials.py`
   - `python baseline_pubmed_alerts.py`
   Sixteen days of silent failure across five cycles is an unresolved operational failure, not a skip. Capture stderr — the likely cause is expired/blocked ClinicalTrials.gov + PubMed API access, a disabled scheduler entry, or a changed hub-root path.
2. **Diagnose the scheduler as a two-job failure.** The agent-state backup recovered (08-01 backup now present) and the gap + hub-state jobs still run, so the fault is isolated to the two baseline-data jobs. Check whether they share a disabled trigger, a common credential/API key, or a hub-root path that drifted (07-17 monitor referenced `/sessions/intelligent-bold-bardeen/...`).
3. **Re-run `python hub_monitor.py`** — its report is itself 16 days stale, so the automated snapshot diffs and the file-freshness/backlog flags are unreliable until it runs again.
4. **Update the tracker with the retatrutide TRIUMPH-2/-3 readout (2026-07-23)** and the planned Q1-2027 BLA; cross-link the retatrutide watchlist entry. (Carried from last cycle — confirm done.)
5. **Update the tracker with the Tzield Stage 3 pediatric approval** if not already logged. (Carried from last cycle — confirm done.)
6. **Patch the zimislecel query** in `baseline_pubmed_alerts.py` — 0 hits despite two active Phase 3 trials strongly suggests the alert is keyed to "VX-880" and missing the "zimislecel" INN.
7. **Do not action gap findings yet** — BRONZE. If pursuing the Health-Equity intersections (esp. Drug Repurposing × Health Equity), run the doctrine's verification (combined-term search + Cochrane/PROSPERO) to lift toward SILVER.
8. **Re-run `project1_literature_gap_analysis.py` only after the PubMed feed recovers** — the current gap report is built on 07-17 data, so re-running now reproduces today's result.

---

*Generated by the Diabetes Research Hub automated monitor — 2026-08-02. Review-only run; no source files modified. All trial/paper figures re-read directly from the source JSON this cycle; breaking-news items web-checked.*
